TY - JOUR
T1 - Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk
AU - AOCS management group
AU - Chornokur, Ganna
AU - Lin, Hui Yi
AU - Tyrer, Jonathan P.
AU - Lawrenson, Kate
AU - Dennis, Joe
AU - Amankwah, Ernest K.
AU - Qu, Xiaotao
AU - Tsai, Ya Yu
AU - Jim, Heather S.L.
AU - Chen, Zhihua
AU - Chen, Ann Y.
AU - Permuth-Wey, Jennifer
AU - Aben, Katja K.H.
AU - Anton-Culver, Hoda
AU - Antonenkova, Natalia
AU - Bruinsma, Fiona
AU - Bandera, Elisa V.
AU - Bean, Yukie T.
AU - Beckmann, Matthias W.
AU - Bisogna, Maria
AU - Bjorge, Line
AU - Bogdanova, Natalia
AU - Brinton, Louise A.
AU - Brooks-Wilson, Angela
AU - Bunker, Clareann H.
AU - Butzow, Ralf
AU - Campbell, Ian G.
AU - Carty, Karen
AU - Chang-Claude, Jenny
AU - Cook, Linda S.
AU - Cramer, Daniel W.
AU - Cunningham, Julie M.
AU - Cybulski, Cezary
AU - Dansonka-Mieszkowska, Agnieszka
AU - Du Bois, Andreas
AU - Despierre, Evelyn
AU - Dicks, Ed
AU - Doherty, Jennifer A.
AU - Dörk, Thilo
AU - Dürst, Matthias
AU - Easton, Douglas F.
AU - Eccles, Diana M.
AU - Edwards, Robert P.
AU - Ekici, Arif B.
AU - Fasching, Peter A.
AU - Fridley, Brooke L.
AU - Gao, Yu Tang
AU - Gentry-Maharaj, Aleksandra
AU - Giles, Graham G.
AU - Goode, Ellen L.
N1 - Funding Information:
Main funding: The scientific development and funding for this project were funded by the following: NIH R01 CA-1491429 (Phelan PI); the US National Cancer Institute (R01-CA076016); the COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 HEALTH F2 2009–223175); the Genetic Associations and Mechanisms in Oncology (GAME‐ON): a NCI Cancer Post-GWAS Initiative (U19-CA148112); the Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07).
Funding Information:
Investigator-specific funding: G.C.-T. is supported by the National Health and Medical Research Council; B.K. holds an ACS Early Detection Professorship (SIOP—‐06—‐258—‐01—‐COUN); L.E.K. is supported by a Canadian Institute of Health Research New Investigator Award (MSH—-87734). AWL is supported by NIEHS T32 training grant (T32ES013678).
Funding Information:
Funding of included studies: Funding of the constituent studies was provided by the California Cancer Research Program (00—‐01389V—‐20170, N01—‐CN25403, 2II0200); the Canadian Institutes of Health Research (MOP—-86727); Cancer Australia; Cancer Council Victoria; Cancer Council Queensland; Cancer Council New South Wales; Cancer Council South Australia; Cancer Council Tasmania; Cancer Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK (C490/A6187, C490/A10119, C490/A10124); the Danish Cancer Society (94—‐222—‐52); the ELAN Program of the University of Erlangen—‐Nuremberg; the Eve Appeal; the Helsinki University Central Hospital Research Fund; Helse Vest; the Norwegian Cancer Society; the Norwegian Research Council; the Ovarian Cancer Research Fund; Nationaal Kankerplan of Belgium; Grant—‐in—‐Aid for the Third Term Comprehensive 10—‐Year Strategy For Cancer Control from the Ministry of Health Labour and Welfare of Japan; the L & S Milken Foundation; the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); the Roswell Park Cancer Institute Alliance Foundation; the US National Cancer Institute (K07—‐CA095666, K07—‐CA143047,K22—‐CA138563, N01—‐CN55424, N01—-PC67001, N01—‐PC067010, N01—‐PC035137, P01—‐CA017054, P01—‐CA087696, P30—-CA072720, P50—‐CA105009, P50-CA136393, R01—‐CA014089, R01—‐CA016056, R01—‐CA017054, R01—‐CA049449, R01—‐CA050385, R01—‐CA054419, R01—‐ CA058598, R01—‐CA058860, R01—‐CA061107, R01—‐CA061132, R01—‐CA067262, R01—‐CA071766, R01—‐CA074850, R01—‐CA080742, R01—‐CA080978, R01—‐CA083918, R01—‐CA087538, R01—‐CA092044, R01—‐095023, R01—‐CA122443, R01—‐CA112523, R01—‐CA114343, R01—‐CA126841, R01—‐CA136924, R03—‐CA113148, R03—‐CA115195, U01—‐CA069417, U01—‐CA071966 and Intramural research funds); the US Army Medical Research and Material Command (DAMD17—‐01—‐1—‐0729, DAMD17—‐02—‐1—‐0666, DAMD17—‐02—‐1—‐0669, W81XWH—-07—-0449, W81XWH—‐10—‐1—‐02802); the US Public Health Service (PSA—-042205); The National Health and Medical Research Council of Australia (199600 and 400281); the German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research (01GB 9401); the State of Baden—‐Wurttemberg through Medical Faculty of the University of Ulm (P.685); the Minnesota Ovarian Cancer Alliance; the Mayo Foundation; the Fred C. and Katherine B. Andersen Foundation; the Lon V. Smith Foundation (LVS—‐39420); the Oak Foundation; the OHSU Foundation; the Mermaid I project; the Rudolf—‐Bartling Foundation; the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Imperial College London, University College Hospital “Womens Health Theme” and the Royal Marsden Hospital; WorkSafeBC 14.
Publisher Copyright:
© 2015 Chornokur et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2015/6/19
Y1 - 2015/6/19
N2 - Background: Defective cellular transport processes can lead to aberrant accumulation of trace elements, iron, small molecules and hormones in the cell, which in turn may promote the formation of reactive oxygen species, promoting DNA damage and aberrant expression of key regulatory cancer genes. As DNA damage and uncontrolled proliferation are hallmarks of cancer, including epithelial ovarian cancer (EOC), we hypothesized that inherited variation in the cellular transport genes contributes to EOC risk. Methods: In total, DNA samples were obtained from 14,525 case subjects with invasive EOC and from 23,447 controls from 43 sites in the Ovarian Cancer Association Consortium (OCAC). Two hundred seventy nine SNPs, representing 131 genes, were genotyped using an Illumina Infinium iSelect BeadChip as part of the Collaborative Oncological Gene-environment Study (COGS). SNP analyses were conducted using unconditional logistic regression under a log-additive model, and the FDR q<0.2 was applied to adjust for multiple comparisons. Results: The most significant evidence of an association for all invasive cancers combined and for the serous subtype was observed for SNP rs17216603 in the iron transporter gene HEPH (invasive: OR = 0.85, P = 0.00026; serous: OR = 0.81, P = 0.00020); this SNP was also associated with the borderline/low malignant potential (LMP) tumors (P = 0.021). Other genes significantly associated with EOC histological subtypes (p<0.05) included the UGT1A (endometrioid), SLC25A45 (mucinous), SLC39A11 (low malignant potential), and SERPINA7 (clear cell carcinoma). In addition, 1785 SNPs in six genes (HEPH, MGST1, SERPINA, SLC25A45, SLC39A11 and UGT1A) were imputed from the 1000 Genomes Project and examined for association with INV EOC in white-European subjects. The most significant imputed SNP was rs117729793 in SLC39A11 (per allele, OR = 2.55, 95% CI = 1.5-4.35, p = 5.66×10-4). Conclusion: These results, generated on a large cohort of women, revealed associations between inherited cellular transport gene variants and risk of EOC histologic subtypes.
AB - Background: Defective cellular transport processes can lead to aberrant accumulation of trace elements, iron, small molecules and hormones in the cell, which in turn may promote the formation of reactive oxygen species, promoting DNA damage and aberrant expression of key regulatory cancer genes. As DNA damage and uncontrolled proliferation are hallmarks of cancer, including epithelial ovarian cancer (EOC), we hypothesized that inherited variation in the cellular transport genes contributes to EOC risk. Methods: In total, DNA samples were obtained from 14,525 case subjects with invasive EOC and from 23,447 controls from 43 sites in the Ovarian Cancer Association Consortium (OCAC). Two hundred seventy nine SNPs, representing 131 genes, were genotyped using an Illumina Infinium iSelect BeadChip as part of the Collaborative Oncological Gene-environment Study (COGS). SNP analyses were conducted using unconditional logistic regression under a log-additive model, and the FDR q<0.2 was applied to adjust for multiple comparisons. Results: The most significant evidence of an association for all invasive cancers combined and for the serous subtype was observed for SNP rs17216603 in the iron transporter gene HEPH (invasive: OR = 0.85, P = 0.00026; serous: OR = 0.81, P = 0.00020); this SNP was also associated with the borderline/low malignant potential (LMP) tumors (P = 0.021). Other genes significantly associated with EOC histological subtypes (p<0.05) included the UGT1A (endometrioid), SLC25A45 (mucinous), SLC39A11 (low malignant potential), and SERPINA7 (clear cell carcinoma). In addition, 1785 SNPs in six genes (HEPH, MGST1, SERPINA, SLC25A45, SLC39A11 and UGT1A) were imputed from the 1000 Genomes Project and examined for association with INV EOC in white-European subjects. The most significant imputed SNP was rs117729793 in SLC39A11 (per allele, OR = 2.55, 95% CI = 1.5-4.35, p = 5.66×10-4). Conclusion: These results, generated on a large cohort of women, revealed associations between inherited cellular transport gene variants and risk of EOC histologic subtypes.
UR - http://www.scopus.com/inward/record.url?scp=84939197812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939197812&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0128106
DO - 10.1371/journal.pone.0128106
M3 - Article
C2 - 26091520
AN - SCOPUS:84939197812
SN - 1932-6203
VL - 10
JO - PLoS One
JF - PLoS One
IS - 6
M1 - e0128106
ER -